DreaMed Diabetes

DreaMed Diabetes is a medical device SaaS company that provides personalized diabetes treatment optimization solutions. Founded in 2014, the company commercialized the first artificial pancreas technology published in NEJM. Since then, DreaMed Diabetes has been actively engaged in the diabetes decision-support tool management space and became the world's first and only FDA-cleared company using CGM/SMBG and insulin pump data for decision-support systems. We offer a clinically validated decision-support system for insulin titration in Type 1 diabetes patients. Our Advisor Pro software, created by diabetes professionals, is based on real-world experience and accelerated through artificial intelligence. With it, any healthcare professional can analyze patient data within seconds and provide recommendations for optimal treatment plans. Through frequent titration adjustments and online monitoring, we can deliver better treatment by reducing A1C levels and the risk of complications.